Biological therapies in psoriasis - revisited

Sârbu, Maria Isabela; Georgescu, Simona Roxana; Tampa, Mircea; Sârbu, A E; Simionescu, Olga

doi:10.1515/rjim-2017-0045

Cited by 6 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The history of PDT is long and marked by several important events. Even though ancient civilizations already knew that various plants could be combined with sunlight to treat skin diseases like vitiligo and psoriasis (21,22), the rediscovery and mechanism elucidation of PDT only occurred at the beginning of the 20th century (23). In 1900, Raab and von Tappeiner first observed an in vitro photodynamic effect and in 1904 von Tappeiner coined the term 'photodynamic' (24,25).…”

Section: Photodynamic Therapy -Generalitiesmentioning

confidence: 99%

Photodynamic therapy: A hot topic in dermato-oncology (Review)

et al. 2019

Self Cite

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a modern, non-invasive therapeutic method used for the destruction of various cells and tissues. It requires the simultaneous presence of three components: a photosensitizer (PS), a light source and oxygen. Precancerous skin lesions are conditions associated with a high likelihood of malignant transformation to squamous cell carcinoma. Data available so far indicate that PDT is a promising treatment method which can be successfully employed in several medical fields including dermatology, urology, ophthalmology, pneumology, cardiology, dentistry and immunology. Numerous authors therefore have studied this technique in order to improve its efficacy. As a result, significant advancement has been achieved with regard to PSs and drug delivery systems. Substantial progress was also obtained with respect to PDT for the treatment of precancerous skin lesions, several authors focusing their efforts on the study of daylight-PDT and on identifying methods of decreasing technique-related pain. This review reports on the most recent findings in PDT, with emphasis on cutaneous precancerous lesions. Contents 1. Introduction 2. Photodynamic therapy-generalities 3. Updates in PDT components 4. Updates in PDT for the management of actinic keratoses 5. Updates in PDT for Bowen's disease and erythroplasia of Queyrat 6. Updates in PDT in the treatment of other precancerous skin lesions: Actinic cheilitis and keratoacanthoma 7. Updates in PDT for lichen sclerosus-a dermatosis with potential for malignant transformation 8. Discussion

show abstract

Section: Photodynamic Therapy -Generalitiesmentioning

confidence: 99%

Photodynamic therapy: A hot topic in dermato-oncology (Review)

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a chronic immunologically mediated dermatosis, affecting 2-3% of the general population (1)(2)(3). Multiple mechanisms are involved in its pathogenesis, such as the hyper-reactivity of T-lymphocytes and dendritic cells, excessive inflammatory cytokine synthesis, accelerated epidermal turnover, epidermal hyperproliferation, reduced keratinocyte differentiation, overexpression of angiogenesis and oxidative stress (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

“…In psoriasis patients, the severity of the skin disease, assessed by the Psoriasis Area Severity Index (PASI), has been analyzed in relation to the prevalence of renal dysfunctions (3,16,18,32,33), purine catabolism (4) and the oxidative stress level (5,6,34). Alteration of purine degradation may be associated with the extension of psoriasis lesions, stimulation of epidermal proliferation and increased DNA peroxidation (6,(35)(36)(37)(38).…”

Section: Introductionmentioning

confidence: 99%

Correlations between related-purine derivatives and renal disorders in patients with psoriasis vulgaris

et al. 2018

Self Cite

View full text Add to dashboard Cite

Recent data suggest that severe psoriasis is an independent risk factor for chronic renal disease. In the present study, we investigated the role of related-purine derivatives as predictors of renal dysfunctions in patients with psoriasis. A prospective study was conducted on a group of 45 patients with psoriasis vulgaris and 45 control cases, monitored over a 5-year period. Alterations of renal function, albumin/creatinine ratio (ACR, mg/g) and UA/creatinine ratio (UACR, mg/mg) were determined in spontaneous urine samples. The status of related-purine derivatives was evaluated by quantification of uric acid (UA, mg/dl), adenosine deaminase (ADA, UI/mg protein), xanthine oxidase (XO, UI/mg protein) and 8-hydroxy-deoxy-guanosine levels (8-OHdG, ng/ml) in serum samples. Compared to the controls, in patients with psoriasis there was an increase in related-purine derivatives levels, which was demonstrated by the elevated serum levels of UA (5.1±0.4 vs. 5.4±1.0, P=0.066), ADA (0.14±0.08 vs. 0.29±0.12, P=0.052), XO (0.22±0.11 vs. 0.42±0.21, P=0.011) and 8-OHdG (3.1±0.05 vs. 8.3±4.7, P=0.002). The serum levels of related-purine derivatives were associated with the severity of psoriasis. In addition, there was a link between the serum levels of related-purine derivatives and markers of renal impairment. There were positive correlations between 8-OHdG and ACR (r=0.452, P=0.028) and between ADA, XO, UA, 8-OHdG and UACR (r=0.297 and P=0.032, r=0.301 and P=0.002, r=0.431 and P=0.027, r=0.508 and P=0.002) and negative correlations between UA, 8-OHdG and the estimated glomerular filtration rate (r=-0.301 and P= 0.036, r=-0.384 and P= 0.002). Thus, severe psoriasis is a risk factor for the development of renal disease.

show abstract

“…It can appear at any age, but two peaks in age of onset have been described: the first between 20 and 30 years and the second between 50 and 60 years [4,5]. Plaque-type psoriasis accounts for approximately 90% of cases and clinically manifests as well-demarcated erythematous plaques covered by silvery-white scales with a predilection for the extensor surfaces of the extremities, scalp, sacral area and umbilicus [3,6]. Psoriasis has a great impact on quality of life; patients often experience depression, anxiety, stigma as well as suicidal behavior [7,8].…”

Section: Introductionmentioning

confidence: 99%

“…The pathogenic model leading to the formation of the psoriatic plaque has however evolved a lot over the years. While the disease was initially considered an epidermal disorder in which various mediators like cyclic adenosine monophosphate, protein kinase C, phospholipase C, eicosanoids, transforming growth factor (TGF)-α had a central role [6,7], in later years the role of T-cells was recognized and interferon (IFN)-γ and interleukin (IL)-12 were considered key players in the pathogenesis of psoriasis [12]. Tumor necrosis factor (TNF)-α was also intensely studied and the biological therapies targeting this cytokine revolutionized the treatment of psoriasis vulgaris [11,13].…”

Section: Introductionmentioning

confidence: 99%

Advances in Understanding the Immunological Pathways in Psoriasis

Georgescu

Tampa

Căruntu

et al. 2019

IJMS

Self Cite

120

View full text Add to dashboard Cite

Psoriasis vulgaris is a chronic, immune-mediated, inflammatory, polygenic skin disorder affecting approximately 2% of the population. It has a great impact on quality of life; patients often experience depression, anxiety, stigma as well as suicidal behavior. Even though psoriasis is one of the most studied dermatological conditions, the pathogenesis of the disease is still not completely elucidated. The complex interactions between keratinocytes, dendritic cells, T-lymphocytes, neutrophils and mast cells are responsible for the histopathological changes seen in psoriasis. The pathogenic model leading to the formation of psoriatic plaques has however evolved a lot over the years. There is now enough evidence to support the role of interleukin (IL) -23, IL-17, IL-22, T helper (Th) -17 cells, Th-22 cells, T regulatory cells, transforming growth factor (TGF)-β1 and IL-10 in the pathogenesis of the disease. Moreover, several inflammatory and anti-inflammatory molecules are currently being investigated, some of them showing promising results. The aim of this paper is to look over the most recent advances in the immunological pathways involved in the pathogenesis of psoriasis vulgaris.

show abstract

Biological therapies in psoriasis - revisited

Cited by 6 publications

References 60 publications

Photodynamic therapy: A hot topic in dermato-oncology (Review)

Photodynamic therapy: A hot topic in dermato-oncology (Review)

Correlations between related-purine derivatives and renal disorders in patients with psoriasis vulgaris

Advances in Understanding the Immunological Pathways in Psoriasis

Contact Info

Product

Resources

About